Polyrizon (NASDAQ:PLRZ) Rating Lowered to Sell at Wall Street Zen

Polyrizon (NASDAQ:PLRZ) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Polyrizon in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

Polyrizon Stock Performance

Shares of NASDAQ PLRZ opened at $12.00 on Friday. The stock’s fifty day simple moving average is $13.83 and its 200 day simple moving average is $9.83. Polyrizon has a 52-week low of $2.88 and a 52-week high of $2,235.00.

Polyrizon (NASDAQ:PLRZ) last announced its earnings results on Wednesday, March 25th. The company reported $2.81 EPS for the quarter.

Institutional Trading of Polyrizon

A hedge fund recently bought a new stake in Polyrizon stock. Jane Street Group LLC bought a new stake in Polyrizon Ltd. (NASDAQ:PLRZ) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned approximately 1.35% of Polyrizon as of its most recent SEC filing.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.